Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAPID: Preoperative Radiotherapy, Chemotherapy, and Immunotherapy in High-Risk Localized Soft Tissue Sarcoma
NCT05774275Phase 2Recruiting
- Sponsor
- Fudan University
- Start
- Aug 2022
- Primary completion
- Aug 2027
- Modality
- Monoclonal Antibodies, Targeted Liposomes, Stealth (PEGylated) Liposomes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab and pegylated liposomal doxorubicin in soft tissue sarcoma (STS), sponsored by Fudan University. Primary endpoint: Objective Response Rate. Started Aug 2022; status: recruiting.
02
Drugs
sintilimabpegylated liposomal doxorubicin
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT05774275.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05774275.